Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to ...

Bausch Health is rumored to be looking to sell its Bausch + Lomb business, which will ease bankruptcy concerns and upgrade ...

The Opal platform offers eye care professionals a complementary tool for patients, featuring order tracking, appointment ...

We have used Biotrue Hydration Boost Rehydrating ... Over.all, we highly recommend the Sensitive Eyes Contact Lens Solution by Bausch + Lomb for anyone with sensitive eyes who wears soft contact ...

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Bausch + Lomb Corporation (BLCO – Research Report) yesterday and set a ...

Federal Reserve's rate cut boosted tech, construction, industrial, machinery, and financial sectors. Top-performing mid-cap ...

Edward Bausch transformed the world of optics with groundbreaking inventions like the iris diaphragm shutter and advanced ...

Bausch + Lomb BLCO. The industry declined 0.6% during this timeframe. The sale, intended to separate both companies, is stuck for quite some time now. Hence, reports of BHC moving forward have ...

The debt refinancing is expected to help the company in the impending spinoff of its eye-care company, Bausch + Lomb. This drugmaker is expected to post quarterly earnings of $1.05 per share in ...

Investing.com -- Bausch + Lomb (NYSE:BLCO) is exploring a potential sale as part of an effort to resolve issues related to its separation from parent company Bausch Health, which is burdened with ...